Добавил:
Upload Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Prescriber's Guide_ Stahl's Ess - Stephen M. Stahl.docx
Скачиваний:
1
Добавлен:
01.07.2025
Размер:
3 Мб
Скачать
☆

Breast Feeding

• Some drug is found in mother’s breast milk

• Trace amounts may be present in nursing children whose mothers are on sertraline

• Sertraline has shown efficacy in treating postpartum depression

• If child becomes irritable or sedated, breast feeding or drug may need to be discontinued

• Immediate postpartum period is a high-risk time for depression, especially in women who have had prior depressive episodes, so drug may need to be reinstituted late in the third trimester or shortly after childbirth to prevent a recurrence during the postpartum period

• Must weigh benefits of breast feeding with risks and benefits of antidepressant treatment versus nontreatment to both the infant and the mother

• For many patients, this may mean continuing treatment during breast feeding

Sertraline: the art of psychopharmacology Potential Advantages

• Patients with atypical depression (hypersomnia, increased appetite)

• Patients with fatigue and low energy

• Patients who wish to avoid hyperprolactinemia (e.g., pubescent children, girls and women with galactorrhea, girls and women with unexplained amenorrhea, postmenopausal women who are not taking estrogen replacement therapy)

• Patients who are sensitive to the prolactin-elevating properties of other SSRIs (sertraline is the one SSRI that generally does not elevate prolactin)

Potential Disadvantages

• Initiating treatment in anxious patients with some insomnia

• Patients with comorbid irritable bowel syndrome

• Can require dosage titration

Primary Target Symptoms

• Depressed mood

• Anxiety

• Sleep disturbance, both insomnia and hypersomnia (eventually, but may actually cause insomnia, especially short-term)

• Panic attacks, avoidant behavior, re-experiencing, hyperarousal

Pearls

✽ May be a type of “dual action” agent with both potent serotonin reuptake inhibition and less potent dopamine reuptake inhibition, but the clinical significance of this is unknown

• Cognitive and affective “flattening” may theoretically be diminished in some patients by sertraline’s dopamine reuptake blocking properties

✽ May be a first-line choice for atypical depression (e.g., hypersomnia, hyperphagia, low energy, mood reactivity)

• Best documented cardiovascular safety of any antidepressant, proven safe for depressed patients with recent myocardial infarction or angina

• May block sigma 1 receptors, enhancing sertraline’s anxiolytic actions

• Can have more gastrointestinal effects, particularly diarrhea, than some other antidepressants

• May be more effective treatment for women with PTSD or depression than for men with PTSD or depression, but the clinical significance of this is unknown

• SSRIs may be less effective in women over 50, especially if they are not taking estrogen

• SSRIs may be useful for hot flushes in perimenopausal women

• For sexual dysfunction, can augment with bupropion, sildenafil, vardenafil, tadalafil, or switch to a non-SSRI such as bupropion or mirtazapine

• Some postmenopausal women’s depression will respond better to sertraline plus estrogen augmentation than to sertraline alone

• Nonresponse to sertraline in elderly may require consideration of mild cognitive impairment or Alzheimer disease

• Not as well tolerated as some SSRIs for panic, especially when dosing is initiated, unless given with co-therapies such as benzodiazepines or trazodone

• Relative lack of effect on prolactin may make it a preferred agent for some children, adolescents, and women

• Some evidence suggests that sertraline treatment during only the luteal phase may be more effective than continuous treatment for patients with PMDD

Suggested Reading

Cipriani A, La Ferla T, Furukawa TA, et al. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev 2010;14(4):CD006117.

DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet 2002;41:1247–66.

Flament MF, Lane RM, Zhu R, Ying Z. Predictors of an acute antidepressant response to fluoxetine and sertraline. International Clin Psychopharmacol 1999;14:259–75.

Khouzam HR, Emes R, Gill T, Raroque R. The antidepressant sertraline: a review of its uses in a range of psychiatric and medical conditions. Compr Ther 2003;29:47–53.

McRae AL, Brady KT. Review of sertraline and its clinical applications in psychiatric disorders. Expert Opin Pharmacother 2001;2:883–92.

SODIUM OXYBATE

SODIUM OXYBATE: THERAPEUTICS

Brands

• Xyrem

see index for additional brand names

Generic?

No

Class

• CNS depressant; GABA-B receptor partial agonist

Commonly Prescribed for

(bold for FDA approved)

• Reducing excessive sleepiness in patients with narcolepsy

• Cataplexy in patients with narcolepsy

• Fibromyalgia

• Chronic pain/neuropathic pain

How the Drug Works

• Gamma hydroxybutyrate (GHB) is an endogenous putative neurotransmitter synthesized from its parent compound, GABA; sodium oxybate is the sodium salt of GHB and is administered exogenously

• Has agonist actions at gamma hydroxybutyrate (GHB) receptors and partial agonist actions at GABA-B receptors

• Improves slow-wave sleep at night, presumably leaving patients better rested and more alert during the day

How Long Until It Works

• Can immediately reduce daytime sleepiness

• Can take several days to optimize dosing and clinical improvement

If It Works

• Improves daytime sleepiness and may improve fatigue in patients with narcolepsy

• Reduces frequency of cataplexy attacks

• May improve sleep physiology and subjective experience of pain and fatigue in patients with fibromyalgia and other chronic pain conditions

If It Doesn’t Work

• Increase dose

• Consider an alternative treatment

Best Augmenting Combos for Partial Response or Treatment Resistance

✽ Sodium oxybate is itself often used as an augmenting therapy to stimulants, modafinil, or armodafinil for excessive sleepiness in narcolepsy

✽ The majority of patients taking sodium oxybate in clinical trials for narcolepsy and cataplexy were taking a concomitant stimulant

• Often used as an augmenting agent for fibromyalgia with SNRIs (e.g., duloxetine, milnacipran) and alpha 2 delta ligands (e.g., gabapentin, pregabalin), but has not been well studied in combination with these agents

Tests

• None for healthy individuals

SODIUM OXYBATE: SIDE EFFECTS

How Drug Causes Side Effects

• Unknown

• CNS side effects presumably due to excessive CNS actions on various neurotransmitter systems

Notable Side Effects

• Headache, dizziness, sedation

• Nausea, vomiting

• Enuresis

Life-Threatening or Dangerous Side Effects

• Respiratory depression, especially when taken in overdose

• Neuropsychiatric events (psychosis, depression, paranoia, agitation)

• Confusion and wandering at night (unclear if this is true somnambulism)

Weight Gain

• Reported but not expected

• May cause weight loss

Sedation

• Occurs in significant minority

What to Do About Side Effects

• Wait

• Lower the dose

• If unacceptable side effects persist, discontinue use

• Discontinue concomitant medications that might be contributing to sedation

Best Augmenting Agents for Side Effects

• Many side effects cannot be improved with an augmenting agent

SODIUM OXYBATE: DOSING AND USE

Usual Dosage Range

• 6–9 g/night in 2 doses, 2.5–4 hours apart

Dosage Forms

• Oral solution 500 mg/mL

How to Dose

• Initial 2.25 g at bedtime and while seated in bed; second dose of 2.25 g should be taken 2.5–4 hours later, also while seated in bed; dosing can be increased by 1.5 g/night every 1–2 weeks; maximum recommended dose 9 g/night

Dosing Tips

✽ Both nightly doses of sodium oxybate should be prepared prior to bedtime, and the prepared second dose should be placed in close proximity to the patient’s bed before the first dose is ingested

• Each dose must be diluted with 2 ounces of water in a child-resistant cup that is supplied by the pharmacist

• The patient will probably need to set an alarm clock in order to wake up for the second dose

• Once prepared, the solution containing sodium oxybate should be consumed within 24 hours in order to minimize bacterial growth and contamination

• Food significantly reduces the bioavailability of sodium oxybate, so the patient should wait at least 2 hours after eating before taking the first dose of sodium oxybate

• It is best to minimize variability in the timing of dosing in relation to meals

• Once-nightly dosing has been studied and found effective in fibromyalgia

Overdose

• Fatalities have been reported; headache, psychomotor impairment, diaphoresis, vomiting (even when obtunded), confusion, agitation, aggression, ataxia, seizures, coma, death

Long-Term Use

• Long-term use has not been studied

• The need for continued treatment should be reevaluated periodically

Habit Forming

• Medical use of sodium oxybate is classified under Schedule III

• Non-medical use of sodium oxybate is classified under Schedule I

• Some patients may develop dependence and/or tolerance; risk may be greater with higher doses

• History of drug addiction may increase risk of dependence

How to Stop

• Taper may not be necessary when used at therapeutic doses; however, it is possible that some patients could develop withdrawal syndrome

Pharmacokinetics

• Metabolized by the liver

• Elimination half-life approximately 30–60 minutes

• Absorption is delayed and decreased by high-fat meals

Drug Interactions

• Should not be used in combination with CNS depressants or sedative hypnotics

Other Warnings/Precautions

✽ Because of the rapid onset of CNS depressant effects, sodium oxybate should only be ingested at bedtime and while in bed

• Sodium oxybate should not be used with alcohol or other CNS depressants, including opiates

• Use only with extreme caution in patients with impaired respiratory function or obstructive sleep apnea

• Patients with history of drug abuse should be monitored closely

• Sodium oxybate may cause CNS effects similar to those caused by other CNS agents (e.g., confusion, psychosis, paranoia, agitation, depression, and suicidality)

Do Not Use

• In patients taking sedative hypnotics

• In patients with succinic semialdehyde dehydrogenase deficiency

• If there is a proven allergy to sodium oxybate (gamma hydroxybutyrate)

SODIUM OXYBATE: SPECIAL POPULATIONS

Renal Impairment

• Dose adjustment is not necessary

• Not excreted renally

• Because sodium oxybate has sodium content, this may need to be considered in patients with renal impairment

Hepatic Impairment

• Reduce dose by one-half and monitor patients closely

Cardiac Impairment

• Not studied

• Because sodium oxybate has sodium content, this may need to be considered in patients with hypertension or heart failure

Elderly

• Safety and efficacy have not been established

• Patients should be monitored closely

Children and Adolescents

• Safety and efficacy have not been established

Pregnancy

• Risk Category B [animal studies do not show adverse effects; no controlled studies in humans]

• Use in women of childbearing potential requires weighing potential benefits to the mother against potential risks to the fetus

✽ Generally, sodium oxybate should be discontinued prior to anticipated pregnancies

Breast Feeding

• Unknown if sodium oxybate is secreted in human breast milk, but all psychotropics assumed to be secreted in breast milk

✽ Recommended either to discontinue drug or bottle feed

SODIUM OXYBATE: THE ART OF PSYCHOPHARMACOLOGY

Potential Advantages

• Less activating than stimulants

• For narcolepsy, may help patients insufficiently responsive to stimulants

• Has the biggest effect size on pain, fatigue, and sleep in fibromyalgia

Potential Disadvantages

• Has abuse potential

• Requires a second dose in the middle of the night

• Potentially more dangerous than other treatments, especially for fibromyalgia or chronic pain, and especially if taken with sedative hypnotics and/or opiates

Primary Target Symptoms

• Sleepiness, fatigue

• Cataplexy

• Painful physical symptoms

• Lack of nonrestorative sleep in fibromyalgia and chronic pain

Pearls

• Sodium oxybate increases slow-wave sleep, thereby improving sleep quality at night and allowing individuals to feel more rested during the day

• Sodium oxybate also increases growth hormone, which is one of the reasons that it has been abused by athletes

✽ There are positive trials for efficacy in fibromyalgia, with improvement in sleep, pain, and fatigue, but an FDA advisory committee voted it down because of safety concerns and the drug is not officially approved for this indication

Suggested Reading

Carter LP, Pardi D, Gorsline J, Griffiths RR. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. Drug Alcohol Depend 2009;104(1–2):1–10.

Moldofsky H, Inhaber NH, Guinta DR, Alvarez-Horine SB. Effects of sodium oxybate on sleep physiology and sleep/wake-related symptoms in patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study. J Rheumatol 2010;37(10):2156–66.

Owen RT. Sodium oxybate: efficacy, safety and tolerability in the treatment of narcolepsy with or without cataplexy. Drugs Today (Barc) 2008;44(3):197–204.

Russell IJ, Perkins AT, Michalek JE, et al. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 2009;60(1):299–309.

Wang YG, Swich TJ, Carter LP, Thorpy MJ, Benowitz NL. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med 2009;15(4):365–71.

SULPIRIDE

SULPIRIDE: THERAPEUTICS

Brands

• Dolmatil

see index for additional brand names

Generic?

Yes

Class

• Conventional antipsychotic (neuroleptic, benzamide, dopamine 2 antagonist)

Commonly Prescribed for

(bold for FDA approved)

• Schizophrenia

• Depression

How the Drug Works

• Blocks dopamine 2 receptors, reducing positive symptoms of psychosis

• Blocks dopamine 3 and 4 receptors, which may contribute to sulpiride’s actions

✽ Possibly blocks presynaptic dopamine 2 autoreceptors more potently at low doses, which could theoretically contribute to improving negative symptoms of schizophrenia as well as depression

How Long Until It Works

• Psychotic symptoms can improve within 1 week, but it may take several weeks for full effect on behavior

If It Works

• Most often reduces positive symptoms in schizophrenia but does not eliminate them

• Most schizophrenic patients do not have a total remission of symptoms but rather a reduction of symptoms by about a third

• Continue treatment in schizophrenia until reaching a plateau of improvement

• After reaching a satisfactory plateau, continue treatment for at least a year after first episode of psychosis in schizophrenia

• For second and subsequent episodes of psychosis in schizophrenia, treatment may need to be indefinite

Соседние файлы в предмете [НЕСОРТИРОВАННОЕ]